Chemokine Modulation of TLR8/9 for Controlled Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, autoimmune diseases, and infectious diseases are limited in effectively regulating the immune response mediated by pattern recognition receptors (PRRs) and chemokines, leading to uncontrolled inflammation and disease progression.
Innovation Solution
Utilizing specific chemokines such as CXCL4, CXCL10, CXCL12, and CCL5 to modulate the activation of toll-like receptors (TLRs) 8 and 9 in plasmacytoid dendritic cells (pDCs), B cells, and macrophages to control the production of pro-inflammatory cytokines and type-I interferons, thereby enhancing therapeutic outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleic acids are used to activate PRRs for immune response, then pathogen recognition and immune activation are improved, but self-nucleic acid recognition causes uncontrolled inflammation and autoimmune diseases
Solution Approach 1:
The patent applies inversion by using inhibitors to block PRR-nucleic acid interactions rather than activating them. Specific inhibitors are designed to prevent TLRs and other PRRs from recognizing nucleic acids, thereby blocking the harmful inflammatory response to self-nucleic acids while preserving the ability to respond to pathogens through alternative mechanisms
Solution Approach 2:
The patent employs intermediary molecules that specifically bind to PRRs or nucleic acids to prevent direct harmful interactions. These intermediaries act as blockers or dampeners that interfere with the nucleic acid-PRR binding pathway, preventing uncontrolled inflammation while allowing controlled immune responses when needed
2Productivity
If chemokines are used to recruit immune cells to tissues, then immune response efficiency is improved, but pro-inflammatory properties cause excessive inflammation and tissue damage
Solution Approach 1:
The patent applies partial action by using specific chemokines or their fragments at controlled levels to achieve sufficient immune cell recruitment without triggering excessive inflammation. Rather than using high concentrations of potent pro-inflammatory chemokines, the invention employs optimized doses that provide adequate immune cell attraction while minimizing harmful inflammatory effects
Solution Approach 2:
The patent modifies parameters of chemokine therapy by altering concentration, duration of administration, or using engineered chemokine variants with reduced pro-inflammatory activity. These parameter changes allow maintenance of effective immune cell recruitment while reducing the harmful inflammatory side effects associated with high-dose or prolonged chemokine exposure
3Reliability
If current PRR-targeting drugs are used for disease treatment, then some therapeutic effects are achieved, but inability to effectively regulate immune response leads to uncontrolled inflammation and disease progression
Solution Approach 1:
The patent implements feedback mechanisms by using drugs that can dynamically regulate PRR activity based on the inflammatory state. The inhibitors are designed to provide negative feedback on overactive PRR signaling, automatically dampening immune responses when inflammation becomes excessive while allowing normal responses when appropriate, thereby achieving balanced and controlled therapeutic effects
Data Source
AI summary
The current invention is related to the prevention and treatment of diseases including cancer, autoimmune disease, and infectious disease using chemokines and the receptors to which they agonize. It has been found that certain chemokines, including CXCL4, CXCL9, CXCL10, and CXCL12 as well as CCL5 have various effects on toll-like receptors in various cell types and these can be utilized for disease treatment and prevention.